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Angiogenesis  plays  a key  role in  tumor  growth,  invasion  and  metastasis  of cancer  diseases  and  there-
fore,  the  inhibition  of  angiogenesis  can  provide  an  important  therapeutic  approach  in cancer  diseases.
This  study  was designed  to  compare  the  anti-angiogenic  activities  of  the  ethanolic  extract  of  Artemisia
sieberi  Besser,  Asteraceae,  and  its  active  substance,  artemisinin  in  both  in  vitro and  in vivo  models.
To  compare  cytotoxicity  level  of ethanolic  extract  of A. sieberi  with  artemisinin,  different  concen-
trations  (1–100  g/ml)  were  tested  using  MTT  assay  on  human  umbilical  vein  endothelial  cells.  The
anti-angiogenic  properties  of serial  concentrations  of  ethanolic  extract  of  A.  sieberi  and  artemisinin
were  examined  on  human  umbilical  vein endothelial  cells  using  a three-dimensional  angiogenesis  assay
(in  vitro  model)  and  in  the  chick  chorioallantoic  membrane  assay  as  in  vivo model.  The effects  of  ethanolic
extract  of  A. sieberi  and  artemisinin  were  also  tested  on  the  expression  of VEGFR-1,  VEGFR-2  and  CD34
genes  using  real-time  PCR.  Ethanolic  extract  of A. sieberi  and  artemisinin  signiﬁcantly  (p < 0.001)  inhibited
the  angiogenesis  in the  human  umbilical  vein  endothelial  cells  culture  whilst  the  ethanolic  extract  of A.
sieberi  showed  higher  effect  in  a concentration-dependent  fashion  (p < 0.001).  The  chick  chorioallantoic
membrane  angiogenesis  was  also  completely  inhibited  by ethanolic  extract  of A. sieberi  at concentra-
tion  of  33  ng/100  l/egg.  The  gene  expression  analysis  showed  that  the  ethanolic  extract  of  A.  sieberi
and  artemisinin  reduced  the  transcription  of VEGFR-1,  VEGFR-2  and  CD34  genes in  a  concentration-
dependent  manner.  This  study  demonstrated  that  the ethanolic  extract  of A.  sieberi  is  strongly  able to
inhibit  the angiogenesis  in  human  umbilical  vein  endothelial  cells  and  chick  chorioallantoic  membrane
models  compared  to the  artemisinin.
ileira© 2016  Sociedade  Bras
ntroduction
Angiogenesis, the process of new blood vessel formation
rom pre-existing vasculatures, is vital process in the embryonic
evelopment, female reproduction cycle and wound healing. It
lso plays a crucial role in the pathogenesis of various diseases
ncluding rheumatoid arthritis, diabetic retinopathy, psoriasis,
uvenile hemangioma and tumor growth and metastasis (Folkman,
995; Koch, 1998; Ferrara and Alitalo, 1999). In cancer disease, this
rocess is an inevitable process for the development and growth of
olid tumors beyond 2–3 mm3. Formation of the new blood vessels
s required to sustain the dissemination of tumor cells; otherwise it
ay  result in an inactivated and dormant tumor disease (Cao et al.,
011). Many pro and anti-angiogenic factors are known to control
he angiogenesis process. The members of the vascular endothelial
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growth factor (VEGF) and ﬁbroblast growth factor gene families are
recognized as pro-angiogenesis agents (Cao et al., 2008; O’Reilly
et al., 1997), while transforming growth factor- (TGF-)  and endo-
statin are introduced as anti-angiogenesis compounds (Roberts,
2008; Nyberg et al., 2005). The balance between these pro- and anti-
angiogenic agents modulates the new blood vasculature growth
in normal condition (Ferrara, 2010; Daniele et al., 2012) and so, it
can be speculated that the disruption of this balance is required to
maintain the progress of tumors. Several anti-angiogenic agents
have been developed to inhibit different stages of angiogenesis in
tumor growth processes. These agents mostly effective in combi-
nation chemotherapy, have become an attractive approach to treat
some cancer diseases (Ellis and Hicklin, 2008; Schmidt, 2009).
The use of herbal drugs as combination therapy has been
suggested by different researchers to inhibit the angiogenesis in
patients with solid tumors (Borchers et al., 1997; Saiki, 2000).
Among these, attention toward the Artemisia-derived products
including artemisinin (ART) has been increased in recent years
(Sagar et al., 2006). There is evidence that the crude extract of
 Ltda. All rights reserved.
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he Artemisia annua (qinghao) has been used as antipyretic, astrin-
ent, sedative and anti-malarial agents from more than 2000 years
go in China (Zhu, 1987; Meshnick et al., 1989). Artemisinin (ART)
s a natural product derived from plant A. annua (qinghao) is
ow used as worldwide combination therapy against multidrug-
esistant species of plasmodium (Klayman, 1985; Miller and Su,
011). Artemisinin is a sesquiterpene lactone containing a peroxide
ridge. This peroxide bridge is believed to be responsible for differ-
nt pharmacological effects of ART (Posner and O’Neill, 2004). The
esquiterpene lactones (SL) are the active constituents of a variety
f medicinal plants including Artemisia sieberi Besser, Asteraceae.
any studies have shown that SL are able to inhibit angiogenesis,
eading to the anti-tumor activity of these compounds (Jeong et al.,
002; Oka et al., 2007; Hayashi et al., 2009; Pratheeshkumar and
uttan, 2011; Yue et al., 2013; Tsuboi et al., 2014).
Recently, artemisinin has been also found to act as a potent anti-
umor agent both in vitro and in vivo (Li and Hickman, 2011). ART
s a cytotoxic agent is known to be able to inhibit the growth of
any cancer cell lines (Efferth et al., 2001, 2003; Efferth, 2006).
t has been also demonstrated that ART and its bioactive deriva-
ives are able to inhibit the angiogenesis activity and metastasis
f some cancer cell lines (Li and Hickman, 2011). Further stud-
es have reported that low concentration of two ART derivatives,
rtesunate and dihydroartemisinin, inhibited angiogenesis in chick
horioallantoic membrane (CAM) and reduced the levels of two
ajor VEGF receptors on human umbilical vein endothelial cells
HUVEC) (Chen et al., 2003). It is also shown that artesunate was
ble to inhibit proliferation and differentiation of human microvas-
ular dermal endothelial in a concentration-dependent manner
Huan-huan et al., 2004). The possibility of angiogenesis inhibition
y ART derivatives in solid tumors can be a promising therapeutic
pproach for prevention of tumor dissemination. Artemisia sieberi
s a typical desert plant that grows in Iran, Palestine, Syria, Iraq,
urkey, Afghanistan and Central Asia (Podlech, 1986) and its ART
ontent was determined for the ﬁrst time, by Arab et al. in 2006.
hey found that the level of artemisinin in the A. sieberi (0.14–0.2%
f dried weight at different seasons) is comparable to that of the
ther species including A. annua (Arab et al., 2006). In further study
hey reported that both the plant extract and a granule formu-
ation derived from the plant extract pose potent anti-coccidial
ffect in broiler chickens (Arab et al., 2009; Kaboutari et al., 2014).
he present study was designed to investigate the anti-angiogenic
ffects of ethanolic extract of A. sieberi (EEA) in comparison to its
ctive substance, artemisinin in HUVEC culture (in vitro model) and
n chick CAM as in vivo model. It is also aimed to compare the effects
f EEA and ART on the gene expression of VEGFR-1, VEGFR-2 and
D34 recognized as an important molecular marker for angiogen-
sis.
aterials and methods
ample preparation
The aerial parts of Artemisia sieberi,  Besser, Asteraceae, were
ollected in September 2012, from Taft County, Yazd Province in
entral part of Iran. The plant was identiﬁed by Prof. Valiallah
ozaffarian. Voucher specimens were deposited and identiﬁed
t the Central Herbarium of Faculty of Science, Tehran Univer-
ity, Tehran, Iran (No. TUH-24118). The dried and ground material
100 g) was subjected to extraction with 500 ml  of a 96% ethanol
t room temperature in three cycles of 72 h each. After each cycle,
he extract was ﬁltered through ﬁlter paper and the solvent was
emoved by vacuum distillation under reduced pressure with a
otary evaporator (38 ◦C). The yield of crude extracts from ethanol
as 7.32 g and kept in −20 ◦C until further use. To prepare theFarmacognosia 26 (2016) 326–333 327
stock solutions, the extract and active substance were dissolved
in dimethyl sulfoxide (DMSO). The mixtures were then ﬁltered
and sterilized using 0.22 m ﬁlter, and kept frozen until analyz-
ing. Serial dilutions of the EEA and ART were freshly prepared from
stock solution before use by dissolving them into the cell culture
media.
Determination of artemisinin in A. sieberi
The A. sieberi extract was  dissolved in ethanol and then,
hydrolyzed by addition of 0.2% NaOH. The hydrolyzed solution was
incubated at 50 ◦C for 30 min  and then neutralized with 0.2 mol/l
acetic acid. The prepared solution was  ﬁltered and stored at −20 ◦C
until HPLC analysis. The HPLC system consisted of a 10 cm × 4 mm
nucleosil C18 column, Waters 510 HPLC pump and Waters 490E
UV detector. The mobile phase was prepared from 20 mmol/l
phosphate buffer (K2HPO4 + KH2PO4) and methanol (60:40, pH
7.9) with run time of 1.5 ml/min. The volume of sample injected
into the chromatograph was  20 l at ﬂow rate of 1.5 ml/min. An
artemisinin standard (Sigma Aldrich Chemical Co.) was used as
external standard to plot the calibration curve of the artemisinin
detected from the extract.
Cell culture and viability assay
The HUVEC was obtained from National Cell Bank of Pasteur
Institute. Cells were cultured in M199 media supplemented with
10% heat inactivated fetal bovine serum (FBS) and 100 IU/ml peni-
cillin plus 100 g/ml streptomycin (Gibco, USA). The cells were
incubated in a humidiﬁed atmosphere of 5% CO2 at 37 ◦C. The cell
viability test was conducted with the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. The HUVEC were
seeded at a density of 1 × 104 cells per well into a 96-well plate
to compare cytotoxicity of EEA with ART on normal cells. After
24 h incubation, cells were exposed to a graded concentration of
1, 3.3, 10, 33 and 100 g/ml of EEA and ART and the incubation was
further continued by 48 h. The maximum concentration of DMSO
added to the cells culture media was 0.1%, and this concentration of
the solvent was always used as control. Subsequently, MTT  reagent
(0.5 mg/ml  in sterile PBS) was added directly to the wells. Cells
were returned to the incubator for 4 h. The formation of insolu-
ble purple formazan from yellowish MTT  by enzymatic reduction
was dissolved in DMSO after removal of supernatant. The viabil-
ity of cells was determined by measuring the absorbance values
at 540 nm using an ELISA reader (BioTek, USA, Gen5 power wave
xs2).
In vitro anti-angiogenic assay
The cytodex-3 microcarrier beads (Sigma Aldrich Chemical Co.)
were pre-swelled in phosphate buffer and they were then rinsed
with M199 media under a sterile hood (Nehls and Drenckhahn,
1995). HUVEC were mixed with cytodex-3-microcarriers at an
appropriate ratio in M199 media supplemented with 20% FBS
and 100 IU/ml penicillin plus 100 g/ml streptomycin. Cells were
allowed to attach to the microcarrier beads in microtube for
4 h at 37 ◦C and the cell-attached beads were then cultured in
collagen matrix by addition of culture media. To compare the anti-
angiogenic effects of EEA with ART, cells were treated with a serial
concentration of 0.001, 0.033, 0.05, 1, 3.3, 10, 33 and 100 g/ml
EEA and ART. After 3–5 days treatment, the anti-angiogenic effects
were monitored microscopically. Results were analyzed after using
a special software package (AE-31; Motic) as previously described
by others (Grifﬁth et al., 2005).
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Table 1
Nucleotide sequences of the primers used for real-time RT-PCR.
Gene Forward primer (5′–3′) Reverse primer (5′–3′) Size
Beta2M ATGCCTGCCGTGTGAAC ATCTTCAAACCTCCATGATG 91
VEGFR-1 CATACTCAACTCCTGCCTTCTC CGCCCTGGAGTCATCAAAC 185
VEGFR-2 GTATGGAGGAGGAGGAAGTATG CCGTCTGGTTGTCATCTGG 173
CD34  ACCCCAGAGTTACCTACCCAG TGTCGTTTCTGTGATGTTTGTTG 152
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Anti-angiogenic effects of EEA and ART on HUVEC
After 3–5 days incubation of the HUVEC, the untreated control
wells showed branching pattern of tube-like capillaries. However,
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Fig. 1. The effects of serial concentrations of 1, 3.3, 10, 33 and 100 g/ml ART and EEA
on human umbilical vein endothelial cells (HUVEC) viability. Cells were incubatedn vivo anti-angiogenic assay
The chick chorioallantoic membrane (CAM) model used to com-
are the in vivo anti-angiogenic activity of EEA and ART was  based
n the procedure described by Kirchner et al. with some modiﬁ-
ations (Kirchner et al., 1996). Brieﬂy, fertilized chicken eggs were
ncubated at 37 ◦C with 55–60% humidity. On day 3 of incubation,
 square hole was made on the outer shell and 0.5–1 ml  albumin
as removed by an 18-gauge hypodermic needle to allow detach-
ent of the CAM development and then, the hole was  carefully
ealed. The eggs were returned to the incubator and the incuba-
ion was continued for 5 days. On day 9 of incubation, a blank
lter disk and discs containing different concentrations of EEA and
RT (1–100 ng/100 l/egg) and their solvent (as negative control)
ere placed on the top of CAM under sterile condition. The num-
ers of newly formed blood vessels in CAM of each treatment
roup were counted on an optical microscope (Olympus, Tokyo,
apan), and the neovascular zones of CAM under the disks were
hotographed.
ene expression analysis
HUVEC cells were exposed to serial concentrations of 1, 3.3,
0, 33 and 100 g/ml of EEA and ART for 24 h, RNA extraction
as done from 106 treated cells using high pure RNA isolation
it (Roche, USA, 11828665001) based on the protocol manual. To
emove genomic contamination, mRNA was treated with DNase I
sing a kit (Fermentas, Lithuania) based on the protocol described
y the manufacturer. Concentrations of RNA were determined by
 UV spectrophotometer (Eppendorf, Germany) and cDNA syn-
hesis was performed using a Revert Aid TM ﬁrst strand cDNA
ynthesis kit (Fermentas, Lithuania). For PCR quantities analysis,
he desired primers of VEGFR-1, VEGFR-2, CD34 and Beta2M (as
nternal control) genes were designed using Allele ID software
Table 1). In the reaction tube, 10 l SYBR Green master mix  (Takara,
apan) was added to 2 l cDNA samples, 0.5 l forward, 10 pmol
everse primers and 7 l nuclease-free water (Qiagen, Hilden, Ger-
any) to accomplish PCR in 20 l of reaction mixture using real
ime PCR instrument (Qiagen 65 HO, USA). The program for reac-
ion was a denatured at 95 for one minute followed by 40 cycles
f initiation at 95 for 10 s, annealing at 56 ◦C for 15 s, elongat-
ng at 72 ◦C for 20 s and a single ﬁnal step at 58 ◦C for 90 s. At
he end of the program, the melting curve was checked and the
ata were analyzed by CT calculation using REST software (Qiagen,
SA).
tatistical analysis
All values were presented as means ± SEM and evaluated for sta-
istical signiﬁcance with one-way ANOVA followed by Bonferroni’s
ost hoc test. A non-linear regression analysis by GraphPad prism
oftware 6.0 was used to obtain GI50 (the concentration caused 50%
rowth inhibition of cultured cells). A p values less than 0.05 was
onsidered signiﬁcant.Results
Artemisinin content of the extract
The retention time for artemisinin in the prepared HPLC system
with ﬂow rate of 1.5 ml/min was  5.4 min. A calibration curve was
constructed using a linear regression algorithm method by plot-
ting the area under curve (AUC) versus different concentrations of
standard solutions. This calibration curve was obtained by injec-
tion of different concentrations of 1, 5, 20, 50 and 100 g/ml of
artemisinin. The artemisinin content of the EEA was 0.18% of dried
weight (DW) of the A. sieberi.
Effect of EEA and ART on the viability of HUVEC
The effects of different concentrations of A. extracts on HUVEC
cultured cells is shown in Fig. 1. As this ﬁgure shows, the EEA and
ART were not able to reduce the number of HUVEC up to concentra-
tion of 3.3 g/ml. However, the exposure of the HUVEC with EEA
and ART at concentrations of 10–100 g/ml was  associated with
signiﬁcant reduction in the number of viable cells (p < 0.05).with ART and EEA for 48 h and the viability of cells was  assessed using MTT  colori-
metric method. Values are expressed as mean ± SEM from at least three independent
experiments. EEA and ART at 1 g/ml did not signiﬁcantly reduce the number of
HUVEC, however, exposure of the HUVEC with 10–100 g/ml of EEA and ART was
associated with signiﬁcant (p < 0.05) decrease in the number of living cells.
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Fig. 2. The inhibitory effects of different concentrations of 0.001, 0.033, 0.05, 1, 3.3,
10,  33 and 100 g/ml ART and EEA on HUVEC capillary tube formation in a three-
dimensional collagen matrix. The assay was  conducted on dextran-coated cytodex-
3  microcarriers and the endothelial cell attached to particles has been migrated
through the collagen matrix. Values are expressed as mean ± SEM from at least three
independent experiments (*p < 0.05 and **p < 0.01 compared to the control).
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Table 2
The concentration caused 50% growth inhibition (GI50) by ethanolic and extract of
A.  sieberi (EEA) and ART on HUVEC culture. The GI50 levels are estimated by a non-
linear regression analysis using the GraphPad Prism software (R2 > 0.97).
Sample GI50 (g/ml)
ART 3.5
EEA 0.024
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Fig. 4. Effects of ART and EEA on chick chorioallantoic membrane (CAM)
angiogenesis. The disks containing different concentrations of ART and EEA
(1–100 ng/100 l/egg) were placed on selected areas of CAM on day 9 and the eggs
were further incubated at 37 ◦C for 48 h. One control and one drug-containing disk
of inhibition (Fig. 5B and C respectively). ART at concentration of
F
d
ahese tube-like vessels formation by HUVEC were signiﬁcantly
educed in the wells exposed to EEA and ART in a concentration-
ependent manner with different potencies (Fig. 2). A picture of
he inhibitory effects induced by 1 g/ml EEA and ART on tube-
ike capillaries formation in HUVEC culture is illustrated in Fig. 3B
nd C. It was found that the endothelial cells attached to par-
icles had been proliferated and migrated through the collagen
atrix in control wells of cell culture plates (Fig. 3A). However,
apillary tube formation was strongly suppressed in wells treated
ith 0.05 to 100 g/ml EEA and 10 to 100 g/ml ART. Among
hese, the concentration of 0.05 g/ml of EEA showed the high-
st inhibitory effects (p < 0.001) on three-dimensional culture of
UVEC (Fig. 2). Treatment of culture cells with ART at the con-
entrations of 0.001–0.05 g/ml had no signiﬁcant effect on the
roliferation of HUVEC. However, 1 g/ml or more of ART sig-
iﬁcantly inhibited cell proliferation (p < 0.001). The 50% growth
nhibitory effects (GI50) of both compounds estimated on capillar-
es formation in HUVEC is shown in Table 2. As this table shows the
I50 in the EEA is signiﬁcantly less than ART, illustrating the higher
nti-angiogenic activity of EEA than ART.
ig. 3. Representative pictures of three independent experiments (10× magniﬁcation) ill
imensional collagen matrix. The picture shows the inhibition of HUVEC sprouting in the p
nd  (C) ART with 20% inhibition.were placed on each CAM and then the numbers of microvessels under the disks
were counted using a light microscope. *p < 0.05, **p  < 0.01 compared to control,
n  = 3.
Anti-angiogenic effects of EEA and ART on CAM
The results of the CAM assay showed that EEA and ART were
signiﬁcantly (p < 0.01) able to impede the in vivo angiogenesis in a
concentration-dependent manner. Fig. 4 shows the anti-angiogenic
effects of EEA and ART on CAM of the chicken embryos. The anti-
angiogenic activity of EEA and ART started at low concentrations of
1 ng/100 l/egg with 10 and 5% of inhibition, respectively (Fig. 4).
The complete anti-angiogenic activity of EEA was  shown at con-
centration of 33, while ART at the same concentration had 75%50 ng/100 l/egg completely inhibited angiogenesis (Fig. 4). How-
ever, exposure of CAM with solvents of tested compounds used as
ustrating the effects of ART and EEA on HUVEC capillary tube formation in a three-
resence of 1 g/ml EEA and ART in which: (A) control, (B) EEA with 100% inhibition
330 Z. Abdolmaleki et al. / Revista Brasileira de Farmacognosia 26 (2016) 326–333
F n chick embryo chorioallantoic membrane (CAM). The pictures show the inhibition of
a hich: (A) Control, (B) EEA with 100% inhibition and (C) ART with 75% inhibition.
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Cont 1 3.3 10 33 100ig. 5. Representative pictures illustrate the inhibitory effects of ART and EEA o
ngiogenesis in the presence of 33 ng/100 l/egg concentration of EEA and ART in w
egative control, did not show any anti-angiogenic activity on the
AM (Fig. 5A).
ffects of EEA and ART on gene expression
Data analysis of the real-time RT-PCR results showed a decrease
n transcript levels of VEGFR-1, VEGFR-2 and CD34 in HUVEC
ulture exposed to the EEA in a concentration-dependent manner.
s shown in Fig. 6A, the concentrations of 3.3, 10 and 33 g/ml
EA diminished transcription of VEGFR-1 to 85.9% (p < 0.01), 71.6%
p < 0.001) and 48.9% (p < 0.001). The ART at the same concentration
as also able to decrease the mRNA expression of VEGFR-2 to
4.1% (p < 0.01), 71% (p < 0.001) and 41.8% (p < 0.001), respectively.
oreover, the mentioned concentrations of EEA reduced tran-
cription of CD34 gene to 89.1% (p < 0.01), 81% (p < 0.01) and 72.1%
p < 0.001) respectively (Fig. 6A). ART also inhibited the expression
f VEGFR-1, VEGFR-2 and CD34 in a concentration-dependent
anner. Fig. 6B demonstrates that ART at the concentrations
f 3.3, 10 and 33 g/ml diminished transcription of VEGFR-1 to
espective values of 88.8% (p < 0.01), 71.6% (p < 0.01) and 65.8%
p < 0.001). The transcription of VEGFR-2 was also reduced by
RT to the levels of 84.8% (p < 0.01), 77.3% (p < 0.01) and 65.3%
p < 0.001), respectively, whereas the expression of CD34 was
blated to 89.9% (p < 0.01), 84.1% (p < 0.01) and 77.1% (p < 0.001),
espectively.
iscussion
It was previously suggested that the anti-malarial artemisinin
erivatives may  also possess antitumor activity (Efferth et al., 2001,
003; Efferth, 2006). Some studies have shown the anti-angiogenic
otential of several artemisinin derivatives in vitro using the cul-
ured HUVEC model (Chen et al., 2003, 2004a,b). In the present
nvestigation, we sought to investigate the in vitro and in vivo
ntiangiogenic activity of ethanolic extract of A. sieberi in com-
arison to artemisinin in three-dimensional culture of HUVEC and
AM of chicks, respectively. Both EEA and ART were able to reduce
he angiogenesis activities in HUVEC culture in a concentration-
ependent manner. However, the EEA showed greater inhibitory
ffects on angiogenesis as it was determined in the level of GI50.
upporting the in vitro ﬁndings, it was found that EEA and ART
ere able to inhibit angiogenesis in CAM of the chicks with higher
otency for EEA. The cytotoxicity assay showed that EEA and ART
re relatively safe on HUVEC at the concentrations inhibiting the
ngiogenesis.Artemisinin and its derivative molecules contain an endoper-
xide bond reacting with a ferrous iron atom leading to cytotoxic
arbon-centered radicals (Olliaro et al., 2001). These carbon-
entered radicals are potent alkylating agents involving in the
Fig. 6. Effects of different concentrations of 1, 3.3, 10, 33 and 100 g/ml EEA
(A)  and ART (B) on the transcription of VEGFR-1, VEGFR-2 and CD34. Data are
expressed as mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01
and ***p < 0.001 compared to the control. Red pluses show the signiﬁcant differences
between EEA and ART with the same meaning as asterisks.
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nti-malarial activity of these compounds. There is evidence
hat the anti-tumor activity of artemisinin is attributed to the
ndoperoxide bond present on the structure of molecules (Galal
t al., 2002). Besides a broad spectrum of activity against
alaria, studies have identiﬁed potential anti-cancer mechanisms
f artemisinin derivatives (ART) such as normalization of upre-
ulated Wnt/-catenin pathway in colorectal cancer (Li et al.,
007). Other anti-cancer activity pathways that ART may  be
nvolved include inhibition of enhanced angiogenesis associated
ith tumors (Wartenberg et al., 2003; Dell’Eva et al., 2004; Chen
t al., 2004a,b; Anfosso et al., 2006; Li and Zhou, 2005; Longo et al.,
006; Wu et al., 2006; Zhou et al., 2007). The antitumor activities
f ART have been reported by some investigators by both in vitro
nd in vivo models of studies (Cao et al., 2009; Chen and Cleck,
009). Efferth et al. have reported that artesunate as a water sol-
ble derivative of artemisinin was potentially effective against a
ariety of cancer cell lines including leukemia and colon tumor
ells. The average level of GI50 estimated against these cell lines
ere 1.11 ± 0.56 M and 2.13 ± 0.74 M,  respectively. However,
he non-small lung cancer cell lines are shown a high level of GI50
25.62 ± 14.95 M).  An intermediate GI50 values was  obtained for
elanomas, breast, ovarian, prostate, CNS, and renal cancer cell
ines (2001).
A potent anti-angiogenic activity against tumor stroma
ells in the rat embryos are shown by artemisinin and
ts derivatives (Firestone and Sundar, 2009). Oh et al.
eported that different thioacetal ART derivatives including
0-a-phenylthiodihydroartemisinins and particularly 10-
-benzenesulfonyl-9-epi-dihydroartemisinin had inhibitory
ctivities against HUVEC proliferation on matrigel. They also
howed that both compounds had strong inhibitory effect on
ngiogenesis in CAM at the concentration of 5 g/egg by 90%
2004). Furthermore, Chen et al. showed that artesunate and
ihydroartemisinin (DHA) signiﬁcantly inhibited angiogenesis in
 concentration-dependent manner with different concentration
f 12.5–50 M and 2.5–50 M,  respectively (2003). Supporting
hese, Huan-huan et al. found that artesunate highly inhibited cell
roliferation and differentiation of human microvascular dermal
ndothelial cells in a concentration-dependent manner ranging
rom 12.5 to 100 M (Huan-huan et al., 2004). The antitumor
ctivities of ART have been also reported in in vivo models by
ew studies. It is found that DHA signiﬁcantly inhibited chick
AM angiogenesis at low concentrations of 5–30 nmol/100 L/egg
Chen et al., 2004a). Jung et al. reported that anti-angiogenic
ctivity of a non acetal-type derivative of artemisinin showed
n CAM model is more or comparable to those of fumagillin and
halidomide with complete inhibitory effects at concentration
0 nmol/egg (Jung et al., 2006).
In the safety assay, we found that EEA and ART did not show
ny toxicity on the HUVEC at low concentrations which these com-
ounds were extensively able to inhibit the angiogenesis. Though
EA and ART reduced the viability of HUVEC at concentration of
0–100 g/ml. A complete anti-angiogenesis was shown by EEA
t concentration of 0.05 g/ml on three-dimensional culture of
UVEC. Data obtained from in vitro assay showed that a partial
nhibition was started by EEA at concentration of 0.001 g/ml,
nd at 0.05–100 g/ml it showed a full anti-angiogenesis effects
ithout any substantial toxic effect on the cells. In the present
tudy, we also found that extract was able to show anti-angiogenic
ffects on chick CAM model in a concentration-dependent man-
er. As the results showed the inhibitory effects of EEA started
t very low concentration of 1 ng/100 l/egg and completed at
3 ng/100 l/egg. These results showed higher anti-angiogenic
ctivity of EEA than ART. It seems the bioactivity of A. sieberi is
ot exclusively due to artemisinin and other components of the
rtemisia sp. Our data are in agreement with the results of EfferthFarmacognosia 26 (2016) 326–333 331
et al. showing that various A. annua extracts have a remarkable
heterogeneity of inhibitory activity, which reﬂecting the biolog-
ical variability between different plant individuals (Efferth et al.,
2011).
VEGF and its tyrosine kinase receptors, VEGFR-1 and mainly
VEGFR-2 (KDR), are known as main mediators of angiogenesis in
both physiological and pathological conditions. VEGF induces a
cascade of signaling pathways through binding to the receptors
resulting in proliferation, migration, survival and vascular perme-
ability (Karkkainen and Petrova, 2000; Kerbel, 2008). VEGF and its
receptors are known as the most commonly targeted molecules
for anti-angiogenic drugs in different types of tumor growth pro-
cesses (Borgstrom et al., 1996; Dvorak, 2002; Yla-Herttuala et al.,
2007). ART have been shown to inhibit proliferation, migration
and tube formation of HUVEC through inhibiting the VEGF binding
to surface receptors on HUVEC and reducing expression of VEGF
receptors Flt-1 and KDR/ﬂk-1 on HUVEC (Chen et al., 2004a,b; Cao
et al., 2009). Artemisinin reduces the expression of the VEGF recep-
tor KDR/ﬂk-1 in various types of tumors and endothelial cells and
slow the growth of human ovarian cancer HO-8910 xenografts
in nude mice (Chen et al., 2004b; Li and Zhou, 2005; Wu et al.,
2006; Zhou et al., 2007; Cao et al., 2009). Induction of apopto-
sis by artesunate in HUVEC is associated with downregulation of
anti-apoptotic protein Bcl-2 and upregulation of pro-apoptotic pro-
tein BAX (Wu et al., 2004). In addition, mRNA expression of 30
out of 90 of angiogenesis-related genes is signiﬁcantly correlated
with the cellular response to ART. This can support the hypothe-
sis that ART exert their anti-tumor activities through inhibition of
tumor angiogenesis (Anfosso et al., 2006). Therefore, in the present
study the real-time RT-PCR test was used to evaluate the EEA and
ART effects on VEGFR-1, VEGFR-2 and CD34 gene expression lev-
els. Data obtained from this study demonstrated that EEA and ART
signiﬁcantly reduced VEGFR-1, VEGFR-2 and CD34 transcript gene
expression.
The synergistic effects of the mixtures of bioactive constituents
and their byproducts contained in the plant extracts may  account
for the apparent enhanced potency of the plant extracts compared
to the individual constituents (Wagner and Ulrich-Merzenich,
2009; Ulrich-Merzenich et al., 2009). The extract of Artemisia
species contain mixtures of organic chemicals that come from dif-
ferent part of plant including leaves, stems, ﬂowers and roots.
The major compounds isolated from Artemisia species include ter-
penoids, ﬂavonoids, coumarins, acetylenes, caffeoylquinic acids,
and sterols (Tan et al., 1998). The reason why  ART, as one of the
main constituent of the Artemisia species did not show great fold
change on the expression of VEGFR-1, VEGFR-2 and CD34 rather
than to the EEA is not clear by this time. But generally, we  can state
that the total extract of the A. sieberi on the gene expression was
greater than that of the individually corresponding active ingre-
dient. These ﬁnding conﬁrmed the anti-angiogenesis activities of
the test compounds demonstrated in vitro and in vivo models of
our study. It suggests that the possible mechanism for inhibition of
tube-like vessels formation by HUVEC may  be through downreg-
ulation of VEGFR-1, VEGFR-2 and CD34 genes in response to the
extracts.
In conclusion, the present study showed that ethanolic extract
of A. sieberi was able to inhibit angiogenesis in both in vitro and
in vivo assay with higher activity than the artemisinin. The results
obtained in the angiogenesis assays were conﬁrmed by RT-PCR
on mRNA gene expressions as determined by a decrease in tran-
script levels of VEGFR-1, VEGFR-2 and CD34 in HUVEC culture
exposed to the EEA. It suggests that the A. sieberi can be a promis-
ing anti-angiogenic agent in complementary chemotherapy. These
ﬁndings provide useful documents for further study to investigate
the therapeutic/preventive activities of A. sieberi extracts in cancer
diseases.
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